Objective. Prevalence of depression during the pregnancy period is a relatively common problem. Since teratogenic effects of concomitant administration of fluoxetine and olanzapine during the organogenesis period is little known, the aim of the present study was to evaluate the teratogenic effects of a co-administration of fluoxetine and olanzapine on rat fetuses. Method. Forty two pregnant rats were divided into seven groups, randomly. The first group received 0.5 ml of normal saline as the control. The second and third groups received fluoxetine in doses of 9 mg/kg and 18 mg/kg, respectively. Olanzapine was injected at 3 mg/kg and 6 mg/kg to the fourth and fifth groups, respectively. The sixth group received 9 mg/kg fluoxetine and 3 mg/kg olanzapine. Finally, the seventh group was administrated with fluoxetine and olanzapine at 18 mg/kg and 6 mg/kg, respectively. Drugs were injected intraperitoneally between day eight and day 15 of the pregnancy. On the 17th day of pregnancy, the fetuses were removed and micro/macroscopically studied. Results. Fetuses of rats received high doses of these drugs showed a significant rate of cleft palate development, open eyelids and torsion anomalies, comparing to control group (P≤0.001). It is concluded that these drugs can lead to teratogenicity, so their concomitant use during pregnancy should be avoided, or if necessary, their doses must be decreased.
Teratogenic Effects of Co-administration of Fluoxetine and Olanzapine on Rat Fetus
GIORGI, MARIO;
2014-01-01
Abstract
Objective. Prevalence of depression during the pregnancy period is a relatively common problem. Since teratogenic effects of concomitant administration of fluoxetine and olanzapine during the organogenesis period is little known, the aim of the present study was to evaluate the teratogenic effects of a co-administration of fluoxetine and olanzapine on rat fetuses. Method. Forty two pregnant rats were divided into seven groups, randomly. The first group received 0.5 ml of normal saline as the control. The second and third groups received fluoxetine in doses of 9 mg/kg and 18 mg/kg, respectively. Olanzapine was injected at 3 mg/kg and 6 mg/kg to the fourth and fifth groups, respectively. The sixth group received 9 mg/kg fluoxetine and 3 mg/kg olanzapine. Finally, the seventh group was administrated with fluoxetine and olanzapine at 18 mg/kg and 6 mg/kg, respectively. Drugs were injected intraperitoneally between day eight and day 15 of the pregnancy. On the 17th day of pregnancy, the fetuses were removed and micro/macroscopically studied. Results. Fetuses of rats received high doses of these drugs showed a significant rate of cleft palate development, open eyelids and torsion anomalies, comparing to control group (P≤0.001). It is concluded that these drugs can lead to teratogenicity, so their concomitant use during pregnancy should be avoided, or if necessary, their doses must be decreased.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
